Recently, a cargo flight carrying YaoPharma manufactured Quetiapine Fumarate Extended- Release Tablets departed for Canada.

Quetiapine Fumarate Extended-Release Tablets is an antipsychotic drug widely used for combined treatment of schizophrenia, bipolar disorder and depression. It is widely accepted by both physicians and patients for its safety and effectiveness. It is a PIV ANDA product co-developed by YaoPharma, a multi-national generic company and a R&D company in US, with the characteristics of high technical barriers and difficult to manufacture.

Quetiapine Fumarate Extended-Release Tablets to be shipped out

Now, besides API export, supplying of Quetiapine Fumarate Extended-Release Tablets to North America makes YaoPharma one of the few Chinese pharmaceutical companies to export finished pharmaceutical products to regulated markets like EU and US. It is a great opportunity for YaoPharma to integrate international resources and enhance independent innovation. It also lays a solid foundation for YaoPharma’s globalization strategy, helping us to fulfill the dream of offering Chinese patients easy access to international standard medicines with lower cost.

Oral solid production line